Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Oxygen to file in Switzerland for phase II clinical trial of Oxycyte in TBI

Feb. 12, 2009

Living Cell Technologies reports interim Diabecell Implants results

Feb. 12, 2009

Vivus initiates second pivotal phase III avanafil trial for erectile dysfunction

Feb. 11, 2009

ConjuChem data confirms PC-DAC lowers glucose in diabetes trials

Feb. 11, 2009

Merrion completes patient enrolment in phase IIb study of Orazol

Feb. 11, 2009

DiaMedica completes treatment in phase IIa clinical trial of DM-99 in type 2 diabetes

Feb. 11, 2009

Arete starts phase IIa AR-9281 trial in type 2 diabetes

Feb. 11, 2009

Novel glucokinase activators jointly reported by Nissan Chemical and Taisho

Feb. 11, 2009

Recent Merck Frosst patent claims new GPR105 antagonists for type 2 diabetes and obesity

Feb. 11, 2009

Priligy receives first regulatory approvals for premature ejaculation

Feb. 10, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...